Author Affiliations
- Andreas Engert1⇑,
- Carlo Balduini2,
- Anneke Brand3,
- Bertrand Coiffier4,
- Catherine Cordonnier5,
- Hartmut Döhner6,
- Thom Duyvené de Wit7,
- Sabine Eichinger8,
- Willem Fibbe3,
- Tony Green9,
- Fleur de Haas7,
- Achille Iolascon10,
- Thierry Jaffredo11,
- Francesco Rodeghiero12,
- Gilles Salles13,
- Jan Jacob Schuringa14,
- the other authors of the EHA Roadmap for European Hematology Research
- 1Universität zu Köln, Cologne, Germany
- 2IRCCS Policlinico San Matteo Foundation, Pavia, Italy
- 3Leids Universitair Medisch Centrum, Leiden, the Netherlands
- 4Université Claude Bernard, Lyon, France
- 5Hôpitaux Universitaires Henri Mondor, Créteil, France
- 6Universitätsklinikum Ulm, Germany
- 7European Hematology Association, The Hague, the Netherlands
- 8Medizinische Universität Wien, Vienna, Austria
- 9Cambridge Institute for Medical Research, United Kingdom
- 10Università Federico II di Napoli, Italy
- 11Université Pierre et Marie Curie, Paris, France
- 12Ospedale San Bortolo, Vicenza, Italy
- 13Hospices Civils de Lyon/Université de Lyon, Pierre-Bénite, France
- 14Universitair Medisch Centrum Groningen, the Netherlands
- Correspondence: a.engert{at}uni-koeln.de
Data supplements
Disclosures and Contributions
Files in this Data Supplement:
ARTICLE FIGURES & DATA
Figures
- Figure 1.
An overview of the current ‘normal’ hematopoiesis field and an outlook on where future research should be directed.
- Figure 2.
A roadmap for research into new technologies in anemias and related disorders.
- Figure 3.
A roadmap for research into dyserythropoietic and hypogenerative anemias.
- Figure 4.
Red blood cell membrane disorders.
- Figure 5.
Proposed priorities for European research on hereditary hemolytic anemias.
- Figure 6.
Synergistic activation of coagulation by contact and tissue factor pathways.
- Figure 7.
Venous thrombosis (VT) incidence increases with age. Incidence rates per 100,000 person-years with 95% confidence intervals. Data are derived from the Tromsø Study (1994–2012), in which 26,853 individuals were followed for a median of 17.7 years, and a total of 710 first VTs occurred.
- Figure 8.
Activation of the adaptive antigen-specific immune response. Potential targets for interventions to reduce Ab production or mitigate destruction. Potential interventions include high-dose IVIG and PDN (prednisolone).
Tables
- Table 1.
Key priorities in a European Anemia Research Roadmap.
- Table 2.
Late-life anemia is frequent in the elderly. Numbers based on a cohort of 19,758 university hospital inpatients and outpatients.203
Vol 101 Issue 2
Jump To
- Article
- Abstract
- Introduction
- Milestones in hematology and the contribution from Europe
- European research policy
- The European Hematology Association Roadmap
- 1.1. Erythropoiesis
- 1.2. Myelopoiesis
- 1.3. Megakaryopoiesis
- 1.4. Lymphopoiesis
- 1.5. Hematopoietic stem cells
- 1.6. Developmental aspects of hematopoiesis
- 1.7. Mesenchymal and other stromal cells
- 1.8. Transcriptional/epigenetic networks
- 1.9. Reprogramming/induced pluripotent stem cells/embryonic stem cells
- 2.1. Hodgkin lymphoma
- 2.2. Diffuse large B-cell lymphoma and Burkitt lymphoma in adults and children
- 2.3. Mantle cell lymphoma
- 2.4. Follicular lymphoma
- 2.5. Marginal zone lymphoma: extranodal, nodal, and splenic forms
- 2.6. T-cell and NK-cell lymphoma
- 2.7. Lymphoma and immune deficiency (including AIDS, post-transplant, and drug-induced immunodeficiency)
- 2.8. Chronic lymphocytic leukemia and other chronic lymphoproliferative disorders
- 2.9. Acute lymphoblastic leukemia
- 2.10. Multiple myeloma and other plasma cell neoplasms
- 3.1. Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
- 3.2. Acute myeloid leukemia
- 3.3. Chronic myeloid leukemia
- 3.4. Myeloproliferative neoplasms
- 4.1. New technologies for anemia and related disorders
- 4.2. Iron-deficiency anemia
- 4.3. Dyserythropoietic and hyporegenerative anemias
- 4.4. Hemolytic anemias, including membrane and enzyme defects
- 4.5. Congenital bone marrow failure, aplastic anemias, and paroxysmal nocturnal hemoglobinuria
- 4.6. Thalassemia and congenital hemoglobinopathies
- 4.7. Iron overload disorders
- 4.8. Anemia in the elderly
- 4.9. Sickle cell disease
- 5.1. Congenital platelet disorders: number and function
- 5.2. Acquired non-immune thrombocytopenia and acquired disorders of platelet function
- 5.3. Primary and secondary immune thrombocytopenia and fetal neonatal alloimmune thrombocytopenia
- 5.4. Heparin-induced thrombocytopenia and other drug-dependent immune thrombocytopenias
- 5.5. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
- 6.1. Genomics in hemostasis
- 6.2. Novel mechanisms for coagulation activation
- 6.3. Venous thromboembolism
- 6.4. Venous thrombosis in aging populations
- 6.5. Bleeding disorders
- 6.6. Women, hemostasis, and thrombosis
- 7.1. Conventional blood products: indications and usage
- 7.2. Plasma-derived and recombinant human plasma proteins
- 7.3. Hemapheresis
- 7.4. Immunological transfusion complications: alloimmunization/transfusion-related immunomodulation/ hemovigilance
- 7.5. Blood-borne infections and hematologic patients: lines of research
- 7.6. Pathogen reduction of blood components
- 7.7. Toward large-scale production of blood cells for transfusion purposes
- 8.1. Infections in HSCT recipients
- 8.2. Infections in neutropenic patients
- 8.3. Infections in non-neutropenic patients other than hematopoietic stem cell transplantation recipients
- 8.4. Infections in primary immune deficiencies
- 8.5. Genetic predisposition factors for infection in hematology and hematopoietic stem cell transplantation patients
- 9.1. Allogeneic stem cell transplantation
- 9.2. Immune-based therapies for hematologic malignancies
- 9.3. The hematopoietic stem cell niche: regulation of hematopoietic stem cell function and significance for hematopoietic stem cell expansion
- 9.4. Human pluripotent stem cells: source of hematopoietic stem cells and hematopoietic progenitor cells
- 9.5. Advanced therapy medicinal products and other cell therapies
- Acknowledgments
- Appendix The authors of the European Hematology Association Roadmap for European Hematology Research
- Footnotes
- References
- Figures & Data
- Info & Metrics